Actinium Pharmaceuticals, Inc.
General ticker "ATNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $45.0M (TTM average)
Actinium Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 9.2%.
Estimated limits based on current volatility of 3.7%: low 1.14$, high 1.23$
Factors to consider:
- Total employees count: 49 (0.0%) as of 2023
- Top business risk factors: Need for additional capital, Operational and conduct risks, Net losses, Dependency on iomab B, Cybersecurity threats
- Current price 10.1% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.08$, 3.68$]
- 2025-12-31 to 2026-12-31 estimated range: [1.31$, 3.96$]
Financial Metrics affecting the ATNM estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -90.37 <= 0.01
- Positive: Investing cash flow per share per price, % of -0.03 > -0.63
- Positive: 19.40 < Shareholder equity ratio, % of 42.60 <= 42.68
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ATNM quotes
Long-term ATNM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.03MM | $0.08MM | $0.00MM |
| Operating Expenses | $35.13MM | $52.00MM | $42.12MM |
| Operating Income | $-34.10MM | $-51.92MM | $-42.12MM |
| Non-Operating Income | $1.09MM | $3.10MM | $3.88MM |
| R&D Expense | $23.14MM | $38.67MM | $30.05MM |
| Income(Loss) | $-33.02MM | $-48.82MM | $-38.24MM |
| Profit(Loss)* | $-33.02MM | $-48.82MM | $-38.24MM |
| Stockholders Equity | $66.48MM | $36.38MM | $32.76MM |
| Assets | $114.19MM | $81.44MM | $76.90MM |
| Operating Cash Flow | $8.64MM | $-47.34MM | $-33.07MM |
| Capital expenditure | $0.37MM | $0.15MM | $0.01MM |
| Investing Cash Flow | $-0.37MM | $-0.15MM | $-0.01MM |
| Financing Cash Flow | $23.11MM | $14.87MM | $29.32MM |
| Earnings Per Share** | $-1.37 | $-1.83 | $-1.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.